Camilla Hansen Ph.D Overview
- Firm
- Novo Holdings
- Primary Position
-
Principal, Seed...
- Primary Industry
-
Healthcare
- Active Board Seats
-
4
- Med. Deal Size
-
000.0
- Med. Valuation
-
000.0
Camilla Hansen Ph.D General Information
Biography
Dr. Camilla Hansen serves as Principal, Seed Investments at Novo Holdings. She serves as Board Member at LimmaTech Biologics and Hemab. She serves as Board Member at Centauri Therapeutics and Hoba Therapeutics. She joined Novo Seeds in June 2018. She brings 10 years of business development experience from early academic start-ups to industry. Most recently, she was responsible for scouting and building new growth platforms for Novozymes A/S. Before that, she held a business development position at Statens Serum Institute (SSI) where she was commercializing preclinical and clinical life science products and projects, in addition to being instrumental in divesting the Vaccine Production business from SSI. From 2009 to 2012 she worked in technology transfer at Wake Forest University Health Sciences in the US where she was involved in out licensing and commercializing early and mid-stage assets, including company creation. She has a Ph.D. in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.
Contact Information
Address
- Tuborg Havnevej 19
- 2900 Hellerup
- 2900 Copenhagen
- Denmark
Camilla Hansen Ph.D Positions (1)
| Firm name | Firm type | Title | Location | Industry | Since |
|---|---|---|---|---|---|
| Novo Holdings | Investor | Principal, Seed Investments | Copenhagen, Denmark | Asset Manager | 0000-00-00 |
Camilla Hansen Ph.D Board Seats (4)
| Company | Industry | Ownership Status | Financing Status | Location | Since |
|---|---|---|---|---|---|
| Centauri Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Nether Alderley, United Kingdom | 0000-00-0 |
| Hemab Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Copenhagen, Denmark | 0000-00-0 |
| Hoba Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Copenhagen, Denmark | 0000-00-0 |
| LimmaTech Biologics | Pharmaceuticals | Privately Held (backing) | Venture Capital-Backed | Schlieren, Switzerland | 0000-00-0 |
Camilla Hansen Ph.D Lead Partner on Deals (3)
| Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
|---|---|---|---|---|---|---|
| LimmaTech Biologics | 01-Feb-2024 | Later Stage VC (Series A) | 0000 | Completed | Pharmaceuticals | Schlieren, Switzerland |
| Hoba Therapeutics | 11-Dec-2023 | 00000 00000 00 | 0000 | Completed | Drug Discovery | Copenhagen, Denmark |
| Centauri Therapeutics | 26-Jan-2022 | 00000 00000 00 | 000.00 | Completed | Drug Discovery | Nether Alderley, United Kingdom |
Camilla Hansen Ph.D Network (90)
Board Members (34)
| Name | Company | Representing | Location | From |
|---|---|---|---|---|
| Thomas Stenfeldt | Hemab Therapeutics | Hemab Therapeutics | Copenhagen, Denmark | 0000-00-00 |
| Mustapha Bakali | LimmaTech Biologics | LimmaTech Biologics | Schlieren, Switzerland | 0000-00-00 |
| 000000000 0 | Centauri Therapeutics | Boehringer Ingelheim Venture Fund | Nether Alderley, United Kingdom | 0000-00-00 |
| 00000 0000 | Hemab Therapeutics | Self | Copenhagen, Denmark | |
| 000000 0000 | LimmaTech Biologics | Adjuvant Capital | Schlieren, Switzerland | 0000-00-00 |
Portfolio Executives (17)
| Name | Company | Role | Deal date | Location |
|---|---|---|---|---|
| Mustapha Bakali | LimmaTech Biologics | Chairman | 01-Feb-2024 | Schlieren, Switzerland |
| Michael Kowarik | LimmaTech Biologics | Co-Founder & Chief Scientific Officer | 01-Feb-2024 | Schlieren, Switzerland |
| 00000000 | LimmaTech Biologics | Chief Operating Officer, Managing Director & Vice President of Clinical and Regulatory Affairs | 01-Feb-2024 | Schlieren, Switzerland |
| 0000000 0 | LimmaTech Biologics | Co-Founder & Board Member | 01-Feb-2024 | Schlieren, Switzerland |
| 00000000 | LimmaTech Biologics | Co-Founder and Chairman of the Board | 01-Feb-2024 | Schlieren, Switzerland |
Fund Team Members (39)
| Name | Investor | Fund | Fund Location |
|---|---|---|---|
| Robert Ghenchev | Novo Holdings | Repair Impact Fund | Copenhagen, Denmark |
| Thomas Grotkjær Ph.D | Novo Holdings | Novo Seeds | Copenhagen, Denmark |
| 000000 00000 | Novo Holdings | 000000 00000 | Copenhagen, Denmark |
| 0000000 0000 | Novo Holdings | 000000 00000 | Copenhagen, Denmark |
| 00000 000000 | Novo Holdings | 000000 00000 | Copenhagen, Denmark |
Camilla Hansen Ph.D Affiliated Funds (2)
| Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
|---|---|---|---|---|---|---|---|---|
| Repair Impact Fund | Novo Holdings | Venture Capital - Early Stage | Closed | 2018 | 00000 | 000000 | 000000 | |
| Novo Seeds | Novo Holdings | Venture Capital - Early Stage | Evergreen | 000000 | 000000 |
Camilla Hansen Ph.D FAQs
-
Who is Camilla Hansen Ph.D?
Dr. Camilla Hansen serves as Principal, Seed Investments at Novo Holdings.
-
How much does Camilla Hansen Ph.D typically invest?
Camilla Hansen Ph.D's median deal size is 000000.
-
What is Camilla Hansen Ph.D’s main position?
Camilla Hansen Ph.D’s primary position is Principal, Seed Investments.
-
What are the contact details for Camilla Hansen Ph.D?
Camilla Hansen Ph.D’s email address is cpLore@mip and his phone number is +45 35 00 00 00.
-
How many active board seats does Camilla Hansen Ph.D hold?
Camilla Hansen Ph.D holds 4 board seats including Centauri Therapeutics, Hemab Therapeutics, Hoba Therapeutics, and LimmaTech Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
